DPSM-Synergy: A Dual-Path Feature Extraction and Synergy Matrix Enhancement Method for Anti-Cancer Drug Synergy Prediction
Journal of Chemical Information and Modeling · 2026
DOI: 10.1021/acs.jcim.5c03141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, 2026. Verfasst von Jinlong Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Information and Control Engineering, Qingdao University of Technology, Qingdao, Shandong 266520, China. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Drug synergy prediction plays a significant role in cancer combination therapy, effectively reducing experimental costs and accelerating the discovery of efficient drug combinations. However, existing computational methods for predicting drug synergy still face significant limitations. Most models rely on a single feature extraction pathway, failing to comprehensively capture the multimodal information in drug molecules. Moreover, they usually ignore the historical synergy patterns between drug pairs and the similarity in cell lines' response patterns to drug combinations, thus failing to effectively use transferable synergy priors to improve model generalizability. Based on the limitations, a novel prediction model, DPSM-Synergy, is proposed. Through integrating a dual-path feature extraction and synergy matrix enhancement strategy, it significantly improves the accuracy of anticancer drug synergy prediction. DPSM-Synergy employs a dual-path architecture composed of a PubChem pretrained model and a graph neural network (GNN) to extract the chemical semantic features and molecular graph features of drugs and innovatively introduces drug synergy matrices and cell line synergy matrices to capture the historical synergy patterns of drug pairs and the response similarity of cell lines to drug combinations, respectively. Experimental findings derived from two benchmark data sets, DrugCombDB and OncologyScreen, indicate that DPSM-Synergy surpasses existing state-of-the-art methods across all evaluation metrics, improving AUC-ROC by 4.00% and 3.57% over the best baseline on the DrugCombDB and OncologyScreen data sets, respectively. This validates the efficacy of the dual-path feature extraction and the synergy matrix enhancement strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Information and Control Engineering, Qingdao University of Technology, Qingdao, Shandong 266520, China.
ORCID-Profile: Wensheng An, Yuanyuan Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Wang, J., An, W., Hang, H., Zhang, C., & Zhang, Y. (2026). DPSM-Synergy: A Dual-Path Feature Extraction and Synergy Matrix Enhancement Method for Anti-Cancer Drug Synergy Prediction. Journal of Chemical Information and Modeling. https://doi.org/10.1021/acs.jcim.5c03141
Vancouver
Wang J, An W, Hang H, Zhang C, Zhang Y. DPSM-Synergy: A Dual-Path Feature Extraction and Synergy Matrix Enhancement Method for Anti-Cancer Drug Synergy Prediction. Journal of Chemical Information and Modeling. 2026. doi:10.1021/acs.jcim.5c03141
BibTeX
@article{Wang2026,
author = {Wang, Jinlong and An, Wensheng and Hang, Huaibin and Zhang, Ciao and Zhang, Yuanyuan},
title = {DPSM-Synergy: A Dual-Path Feature Extraction and Synergy Matrix Enhancement Method for Anti-Cancer Drug Synergy Prediction},
journal = {Journal of Chemical Information and Modeling},
year = {2026},
doi = {10.1021/acs.jcim.5c03141}
}
EUVIMED